Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Next Previous
Trial Profile

A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Padnarsertib (Primary) ; Niacin
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TEACH
  • Sponsors Antengene Corporation

Most Recent Events

  • 27 Apr 2024 Status changed from recruiting to discontinued. (Because the sponsor modified the study-product development strategy.)
  • 18 Jun 2021 According to an Antengene Corporation media release, the company has initiated dosing in Mainland China following the initial dose-escalation phase in Taiwan.
  • 14 Apr 2020 According to an Antengene Corporation media release, first patient has been successfully enrolled and dosed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top